Overview Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research Status: Recruiting Trial end date: 2025-05-15 Target enrollment: Participant gender: Summary A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia Phase: Early Phase 1 Details Lead Sponsor: Anhui Provincial HospitalCollaborator: Leman Biotech Co., Ltd